Related Experiment Videos
Hepatitis C in the liver transplant recipient: current understanding and treatment
1Division of Gastroenterology/Hepatology and Liver Transplantation Program, Oregon Health and Sciences University, PO Box 1034, P3-GI, 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA. hugo.rosen@med.va.gov
Insights
Hepatitis C virus (HCV) recurrence after liver transplant is common. Identifying patients at risk for progressive liver allograft injury is crucial for effective antiviral therapy and improved outcomes.
Area of Science:
- Hepatology
- Transplantation Immunology
- Virology
Background:
- Hepatitis C virus (HCV)-related liver disease is a primary reason for liver transplants globally.
- Recurrence of HCV infection post-transplant is nearly universal, with most patients showing histologic evidence of hepatitis.
- While short-term survival is comparable to other liver failure causes, a significant percentage develop graft cirrhosis within five years.
Purpose of the Study:
- To highlight the significance of HCV recurrence after orthotopic liver transplantation.
- To emphasize the need for early identification of patients at risk for progressive HCV-related allograft injury.
- To underscore the importance of optimizing antiviral therapies based on patient risk stratification.
Main Methods:
- Review of existing literature and clinical data on HCV recurrence post-liver transplantation.
- Analysis of outcomes, including graft survival and development of cirrhosis.
- Focus on the timeline for assessing disease progression and patient prognosis.
Main Results:
- HCV recurrence, evidenced by viremia, is almost universal after liver transplantation.
- Histologic evidence of recurrent hepatitis is common in the majority of transplanted patients.
- Approximately 20-30% of HCV-positive recipients develop allograft cirrhosis within five years post-transplant.
Conclusions:
- Disease outcomes in HCV-positive liver transplant recipients can be defined within a relatively short follow-up period.
- Identifying patients prone to progressive HCV-related allograft injury is essential.
- Optimizing current antiviral treatment strategies is critical for improving long-term results in this patient population.
Abstract:
Hepatitis C virus (HCV)-related liver disease is the leading indication for orthotopic liver transplantation worldwide. Recurrent HCV infection as defined by viremia after transplantation is nearly universal, with histologic evidence of recurrent hepatitis present in the majority. Although short-term survival appears to be similar to that in other causes of liver failure, it has recently been demonstrated that approximately 20-30% of HCV-positive patients develop allograft cirrhosis by 5 years. Therefore, it is possible to define disease outcomes within a relatively short period of follow-up. Identification of patients who are likely to develop progressive HCV-related allograft injury is important to optimize results of current antiviral therapy.